Eupraxia Pharmaceuticals Inc
EPRX
Get informed when a big investor buys or sells
+ FollowMarket Cap$223.48M
Close$
$1.45
77.2% downside
Current Fair Value
77.2% downsideOvervalued by 77.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $223.48 Million |
|---|---|
| Enterprise Value | $172.99 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.03 |
| Beta | 1.5 |
| Outstanding Shares | 66,221,815 |
Return
| Return on Equity | -45.08% |
|---|---|
| Return on Assets | -42.30% |
| Return on Invested Capital | -47.52% |
Valuation & Multiples
| P/E Ratio | -6.54 |
|---|---|
| PEG | -10 |
| Price to Sales | - |
| Price to Book Ratio | 6.34 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -2.78 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 11, 2026
EPS Estimate
$-0.25
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 3, 2026
EPS Estimate
$-0.26
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 39.20%▲ 4.28% |
|---|---|
| Total Invested | $158.26M▲ 50.56% |
| Investors Holding | 55▲ 19.00% |
ESG Score
No data